<b>Aequus Highlights Study Indicating Vistitan as the Most Effective Treatment for Glaucoma</b> <br /> <br /> VANCOUVER, British Columbia, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) today acknowledged the research results presented at the American Academy of Ophthalmology in San Francisco that revealed bimatoprost 0.03%, branded as PrVistitanTM and promoted by Aequus in Canada, as the most efficacious topical treatment currently available for glaucoma and ocular hypertension in terms of intraocular pressure. The study, conducted by Dr. Paul Harasymowycz and his team, assessed the comparative efficacy of latanoprostene bunod to other treatments for intraocular pressure reduction at three months. The study concluded that bimatoprost 0.03% is the most successful in decreasing intraocular pressure, and therefore reducing glaucoma risk.1 <br /> <br /> “In treating a disease where every millimetre of ocular pressure control is important, the data continues to support the use of Vistitan over the competition due to its effective bimatoprost 0.03% formulation,” said Ian Ball, CCO of Aequus. “This study adds to a growing body of evidence that Vistitan, the only bimatoprost 0.03% formulation currently marketed in Canada, is the most effective product available for treating glaucoma and is the cornerstone of our rapidly expanding ophthalmology franchise in Canada.” <br /> <br /> Bimatoprost 0.03% is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension. Vistitan is currently the only marketed version of 0.03% bimatoprost ophthalmic solution for this indication in Canada and demonstrates the best ratio of safety to efficacy for this strength of the molecule. Aequus began Canadian promotional activities for Vistitan in May 2016, on behalf of its partner.